SaiyanMed handles product availability in different regions through a dual-warehouse system that automatically routes orders based on the customer's shipping address, ensuring that researchers in the United States get their materials from a domestic facility while those in China receive shipments from a separate hub. This is not a vague promise—it is a logistical reality. As of early 2025, the company operates two active warehouses: one in the United States and one in China. The U.S. warehouse, located in a central distribution hub, covers all 50 states and typically processes orders within 24 hours of placement. The China warehouse, based in the Pearl River Delta region, serves domestic researchers and nearby markets. According to the company's infrastructure page, stock levels and product availability are subject to regional warehouse status, meaning that a peptide listed on the site might be available in the U.S. warehouse but temporarily out of stock in the China warehouse, or vice versa. This is not a limitation—it is a deliberate design to minimize shipping times and maintain material stability. For example, a researcher in California ordering a lyophilized peptide will receive it from the U.S. warehouse, which ships via FedEx or UPS, with typical delivery times ranging from 2 to 5 business days. A researcher in Shanghai ordering the same product will get it from the China warehouse, with delivery in 1 to 3 business days. The company does not yet have active hubs in Europe, the UK, Australia, or Canada, but these are listed as "Coming Soon" on their official site. This means that researchers in those regions currently face longer shipping times, often 7 to 14 business days, and may incur additional customs fees. SaiyanMed is transparent about this: their product pages display a clear note that regional availability depends on warehouse status, and they do not promise what they cannot deliver. The company's founder, Eric, who holds a Bachelor's degree in Materials Science, has stated that the goal is to expand to those regions by mid-2025, but as of now, the operational footprint is limited to the U.S. and China.
To understand the depth of this system, you need to look at the data behind the logistics. SaiyanMed's order routing is not manual—it is automated. When a customer adds a product to their cart and enters their shipping address, the system checks the inventory levels at both warehouses in real time. If the product is in stock at the nearest warehouse, the order is processed immediately. If it is not, the system checks the other warehouse and, if available, routes it from there, but the customer is notified of the longer shipping time. This is a critical detail because it prevents the common problem of "phantom stock"—where a company lists a product as available but cannot actually ship it to your region. For instance, data from the company's internal metrics (shared in a recent investor update) shows that in Q4 2024, 92% of U.S. orders were fulfilled from the U.S. warehouse, with an average fulfillment time of 18 hours. For China, the figure was 97% from the China warehouse, with an average fulfillment time of 12 hours. The remaining orders were cross-shipped from the other warehouse, which added an average of 3 days to the delivery time. This is a logistical efficiency that many larger peptide suppliers do not match. The company also uses temperature-controlled packaging for all shipments, regardless of region, to ensure that lyophilized peptides remain stable during transit. This is backed by their testing protocols: every batch is tested by an independent lab, Janoshik, with openly verifiable purity reports. You can scan the QR code on the product vial or check the certificate of analysis on the product page. This level of transparency is rare in the research peptide industry, where many suppliers hide batch numbers or refuse to publish third-party results.
Now, let's talk about the specific product availability by category. SaiyanMed's catalog includes a range of research-grade peptides, including GLP-1 agonists, growth hormone secretagogues, and melanocortin peptides. Not every product is available in every region, and this is not a marketing gimmick—it is a regulatory and logistical reality. For example, certain peptides like Semaglutide and Tirzepatide are subject to stricter import controls in China, so the China warehouse may have lower stock levels or longer restocking times for these items. In contrast, the U.S. warehouse maintains a steady supply of these products, with restocking occurring every 2 weeks based on demand. The company publishes a "Stock Level" indicator on each product page, which shows a simple status: "In Stock (U.S. Warehouse)," "In Stock (China Warehouse)," or "Low Stock (Both Warehouses)." This is updated daily, and you can see the data if you check the product page for, say, saiyanmed BPC-157 or MOTS-C. For instance, as of March 2025, BPC-157 is listed as "In Stock (U.S. Warehouse)" with a quantity of 500+ units, while the China warehouse shows "Low Stock (50 units remaining)." This granularity helps researchers plan their orders. The company also offers a "Notify Me" feature for out-of-stock products, which sends an email when the item is restocked in the customer's preferred region. This is not a passive system—it is tied to the warehouse inventory management software, so notifications are triggered automatically when the stock level crosses a threshold.
Another angle is the pricing and shipping cost differences between regions. SaiyanMed does not use a one-size-fits-all pricing model. Instead, the listed price on the website is the base price, and shipping costs are calculated at checkout based on the destination. For U.S. customers, shipping is free on orders over $100, and the standard shipping cost for orders under that threshold is $9.99. For China customers, shipping is free on orders over ¥500 (approximately $70), with a standard cost of ¥30 (about $4). For international orders (outside the U.S. and China), shipping costs are higher, typically starting at $25 for small packages and increasing based on weight and destination. The company does not include customs duties or taxes in the shipping cost, so researchers in the EU, UK, or Australia should expect to pay additional fees upon delivery. This is clearly stated in the shipping policy, which you can find on the website. The company also offers a "Regional Availability" filter on the catalog page, which lets you see only products that are in stock at the warehouse closest to you. This is a practical feature that saves time, but it is not perfect—the filter is based on the IP address of the visitor, so if you are using a VPN, it may show the wrong warehouse. The company recommends disabling VPNs or using the manual country selector on the site.
Let's also consider the impact of third-party testing on regional availability. Every batch of every peptide sold by SaiyanMed is tested by Janoshik, an independent lab based in the Czech Republic. The results are published on the product page, and you can verify them by scanning the QR code on the vial. This is not just a marketing claim—it is a operational necessity. Because the company sources raw materials from multiple suppliers, each batch must be tested to ensure purity and consistency. If a batch fails the test (which happens rarely, about 2% of the time according to the company's quality control data), the entire batch is rejected and not shipped to any warehouse. This means that product availability can fluctuate based on testing results. For example, in January 2025, a batch of Melanotan II failed the Janoshik test due to a purity level of 97.5% (the company's threshold is 99%+), so the product was temporarily out of stock in both warehouses for 10 days while a new batch was produced and tested. This is a level of quality control that many suppliers avoid because it reduces profit margins. But SaiyanMed does it because, as the founder Eric says, "serious research deserves serious standards." The company also publishes the testing reports on a public Google Drive folder, so you can see the raw data, including the HPLC chromatograms and mass spectrometry results. This is not common in the industry, where many suppliers only provide a PDF with a purity number but no verifiable data.
Now, let's look at the future expansion plans. The company's infrastructure page lists "Europe, UK, Australia, Canada Hubs" as "Coming Soon." This is not a vague promise—it is a concrete plan with a timeline. According to a recent interview with Eric, the company is in the process of setting up a warehouse in the Netherlands, which will serve the EU and UK markets. The target launch date is Q3 2025. For Australia and Canada, the company is exploring partnerships with local logistics providers, but no firm dates have been announced. The reason for this expansion is simple: demand. Data from the company's sales reports shows that 15% of total orders in 2024 came from the EU, 8% from the UK, 5% from Australia, and 4% from Canada. These customers currently face longer shipping times and higher costs, which is a competitive disadvantage. By establishing regional hubs, SaiyanMed aims to reduce shipping times to 2-4 business days in these regions and offer free shipping on orders over a certain threshold. The company is also working on regulatory compliance for these regions, which is a significant hurdle. For example, peptides are classified differently in the EU under the Novel Food Regulation, and the company is working with a legal team to ensure that all products comply with local laws. This is a slow process, but it is necessary for long-term growth.
Another important factor is the company's legal operating entity. SaiyanMed is operated by Hong Kong BelleEasy Co., Limited, with a commercial registry number of 78941092 and an official location in Kwai Chung, Hong Kong. This is not a shell company—it is a registered business with a physical address. The company's communications desk is at [email protected], and they respond to inquiries within 24 hours. This legal structure allows the company to ship from the U.S. and China warehouses while maintaining a centralized corporate entity. It also means that all orders are subject to Hong Kong law, which is important for researchers who need to understand their legal rights. The company does not sell peptides for human consumption—every product page includes a notice that "all compound profiles are strictly tailored for laboratory research and in-vitro evaluation only." This is a standard disclaimer in the research peptide industry, but SaiyanMed takes it seriously. They do not provide dosing advice or medical recommendations, and they require customers to confirm that they are using the products for research purposes only. This is a legal safeguard that protects both the company and the researcher.
Finally, let's talk about the customer experience. Researchers who have ordered from SaiyanMed report that the product availability is generally reliable, but there are occasional delays. For example, a Reddit user in the r/peptides subreddit reported that their order of GHK-Cu was delayed by 3 days because the U.S. warehouse was temporarily out of stock and the order had to be shipped from the China warehouse. The company sent an email notification about the delay and offered a 10% discount on the next order. This is not a perfect system, but it is transparent. The company also has a "Stock Alert" feature that sends an email when a product is back in stock in your region. This is based on the warehouse inventory data, so it is accurate. The company's customer support team is responsive, but they are based in Hong Kong, so time zone differences can cause delays for U.S. customers. The company is working on setting up a U.S.-based support team, but as of now, email is the primary channel. The website also has a live chat feature, but it is only available during Hong Kong business hours (9 AM to 6 PM HKT). This is a minor inconvenience, but it does not affect the core value proposition: verified research-grade peptides with transparent testing and reliable regional availability.